Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565511 · ClinicalTrials.gov registry record · Phase 2
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
NCT02565511 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 480 participants.
The verdict
NCT02565511, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
Study Summary
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Interventions
- DRUG CNP520
- BIOLOGICAL CAD106 Immunotherapy
- OTHER Placebo to CAD106
- OTHER Placebo to CNP520
- OTHER Alum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02565511
The ClinicalTrials.gov registry entry for NCT02565511 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CNP520 is the first listed.
NCT02565511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02565511 about?
NCT02565511 is a clinical study titled "A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease". The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their a...
What is the current status of trial NCT02565511?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2015-11-30. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT02565511?
The interventions under investigation include: CNP520 (DRUG), CAD106 Immunotherapy (BIOLOGICAL), Placebo to CAD106 (OTHER), Placebo to CNP520 (OTHER), Alum (OTHER).
Who is sponsoring clinical trial NCT02565511?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.